EBMT Distinguished Interview | Optimizing Induction Therapy Before ASCT: From Past to Future

EBMT Distinguished Interview | Optimizing Induction Therapy Before ASCT: From Past to Future

Induction therapies with high remission rates, combined with high-dose chemotherapy and autologous stem cell transplantation (ASCT), have significantly improved the prognosis for multiple myeloma (MM) patients. Despite this, patients still inevitably experience disease progression or relapse. One of the key goals in this research field is how to maintain remission in patients after induction therapy and ASCT. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting took place in Glasgow, UK, from April 14 to 17, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with hematological diseases and cancers. At this conference, Professor Jean-Luc Harousseau, Chairman of the French National Health Authority and Director of the René Gauducheau Cancer Center at the University of Nantes, delivered an insightful presentation on optimizing induction therapy strategies for multiple myeloma patients before ASCT. "Hematology Frontier" invited Professor Harousseau to share his insights on continuously optimizing pre-ASCT induction therapy for multiple myeloma patients.
Professor Wei Yu Shares Research Progress in NMIBC Treatment | EAU24 Expert Commentary

Professor Wei Yu Shares Research Progress in NMIBC Treatment | EAU24 Expert Commentary

Transurethral resection of bladder tumors (TURBt) is the conventional treatment for non-muscle-invasive bladder cancer (NMIBC). Patients are stratified into low, intermediate, high, and very high risk categories, with different postoperative bladder instillation treatments and follow-up monitoring strategies for different risk patients. Several advancements in NMIBC research were presented at the recent EAU conference, and "Oncology Frontier-Urology Frontier" invited Professor Wei Yu from Peking University First Hospital to share related research findings.
 Recent Advances in the Treatment of Advanced Urothelial Carcinoma: Insights from Dr. Jens Bedke

 Recent Advances in the Treatment of Advanced Urothelial Carcinoma: Insights from Dr. Jens Bedke

Platinum-based combination chemotherapy remains the cornerstone of treatment for advanced urothelial carcinoma (UC), but it still falls short of meeting long-term survival needs. At the 39th Annual Congress of the European Association of Urology (EAU24) held in Paris, France, Dr. Jens Bedke, from Klinikum Stuttgart Katharinen Hospital, shared the results of the EV-302/KEYNOTE-A39 study. Urology Frontier had the privilege of inviting renowned expert Dr. Jens Bedke to discuss the current status of immunotherapy, recent major advances in clinical trials, and future directions in UC treatment.
Professor Vasileios Sakalis on the Value of Artificial Intelligence in the Diagnosis and Treatment of Urological Tumors

Professor Vasileios Sakalis on the Value of Artificial Intelligence in the Diagnosis and Treatment of Urological Tumors

Artificial Intelligence (AI) is transforming the diagnostic and treatment approaches for urological tumors, especially with significant advancements in intelligent imaging and pathology, potentially becoming an indispensable tool for clinicians. Dr. Vasileios Sakalis, a urologist from the Hippokrateion General Hospital of Thessaloniki, Greece, presented a comprehensive review on the application of AI in urological tumors at the conference. During an on-site interview with "Oncology Frontier-Urology Frontier," he shared further insights on the applications of AI.
2024 CUDA Yanqi Lake Conference | Professor Xiongjun Ye Shares Recent Breakthroughs in Renal Cell Carcinoma Treatment

2024 CUDA Yanqi Lake Conference | Professor Xiongjun Ye Shares Recent Breakthroughs in Renal Cell Carcinoma Treatment

The ASCO-GU, a premier academic conference in urologic oncology, at the beginning of the year sparked academic enthusiasm in 2024, receiving over 140 abstracts related to renal cell carcinoma (RCC). Professor Xiongjun Ye from the Chinese Academy of Medical Sciences Cancer Hospital presented a report on the significant progress in RCC treatment from the ASCO-GU at the 4th Yanqi Lake Conference of the Chinese Medical Association Urology Surgery Branch, summarizing the essence for all to appreciate.
2024CUDA Conference | Professor Benkang Shi: Focus on Unmet Needs of mHSPC Patients, Achieve Stratified Treatment for Key Populations

2024CUDA Conference | Professor Benkang Shi: Focus on Unmet Needs of mHSPC Patients, Achieve Stratified Treatment for Key Populations

The current treatment status of mHSPC patients in China and the need for further improvement have drawn attention. Recently, at the "4th Annual Conference of the Urology Physicians Branch of the Chinese Medical Association (2024)" held in Beijing, Professor Benkang Shi from Qilu Hospital of Shandong University shared insights on "Long-term Management of mHSPC Patients with Novel Hormonal Therapy Schemes." Following the conference, "Oncology Frontier - Urology News" invited Professor Benkang Shi to share insights on the diagnosis and treatment status of mHSPC, stratification of key populations, and personalized treatment
2024CUDA Conference | Professor Qiang Wei: Early Initiation of Novel Hormonal Therapy Brings More Benefits to Patients

2024CUDA Conference | Professor Qiang Wei: Early Initiation of Novel Hormonal Therapy Brings More Benefits to Patients

The "4th Annual Conference of the Urology Physicians Branch of the Chinese Medical Association (2024)" was successfully held in Beijing from April 13th to 14th. During the conference, Professor Qiang Wei from West China Hospital, Sichuan University, shared insights on "Standard Treatment of mHSPC in the Era of Novel Hormonal Therapy." Subsequently, "Oncology Frontier - Urology News" invited Professor Qiang Wei to discuss the significance of early initiation of novel hormonal therapy for mHSPC patients, the comparison between dual and triple therapy, and precise treatment selection strategies.
BISC 2024丨Professor Junyan Qu: Interpretation of Anthrax Diagnosis and Treatment Plan (2023 Edition)

BISC 2024丨Professor Junyan Qu: Interpretation of Anthrax Diagnosis and Treatment Plan (2023 Edition)

Anthrax is a zoonotic infectious disease caused by Bacillus anthracis infection, which still occurs sporadically in some areas of China. Anthrax can manifest in various clinical forms, with pulmonary anthrax having a mortality rate of over 80% and requiring management as a Class A infectious disease. In order to further standardize the clinical diagnosis and treatment of anthrax, the National Health Commission issued the "Anthrax Diagnosis and Treatment Plan (2023 Edition)." At the recent Fourth National Congress of the Chinese Society of Infectious Diseases (BISC 2024), Professor Junyan Qu, the secretary-general of the conference and from the Infectious Diseases Center of West China Hospital, Sichuan University, interpreted the diagnosis and treatment plan based on case studies. The summary is presented below.
Professor Ning Shen ‘s Team: Mechanisms of Resistance to Cefiderocol in Highly Virulent Klebsiella pneumoniae | ESCMID Global 2024

Professor Ning Shen ‘s Team: Mechanisms of Resistance to Cefiderocol in Highly Virulent Klebsiella pneumoniae | ESCMID Global 2024

With the escalating issue of antimicrobial resistance globally, newly emerged resistant strains pose a serious threat to public health. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study by Professor Ning Shen 's team from Peking University Third Hospital (Abstract No.: E0451) focused on the resistance issues of cefiderocol, a drug not yet marketed in China. The study discovered that cefiderocol can induce resistance in vitro and amplify the blaSHV-12 gene. Long-read sequencing technology demonstrated its potential in the rapid and accurate detection of resistance gene amplification, offering a new tool for future resistance research.
Professor Hongfei Duan：Advances in Diagnosis and Treatment of Mycobacterium avium Complex (MAC) Pulmonary Disease

Professor Hongfei Duan：Advances in Diagnosis and Treatment of Mycobacterium avium Complex (MAC) Pulmonary Disease

Non-tuberculous mycobacteria (NTM) refers to all mycobacteria other than Mycobacterium tuberculosis and Mycobacterium leprae. NTM most commonly affect the lungs, causing NTM pulmonary disease (NTM-PD), which can even lead to disseminated disease in immunocompromised individuals. In recent years, with changes in the environment, updates in detection technology, and increased awareness among physicians, the incidence of NTM-PD has been steadily increasing, with Mycobacterium avium complex (MAC) pulmonary disease being the most common worldwide. At the recent Fourth National Conference of the Chinese Medical Association on Bacterial and Fungal Infections (BISC 2024), Professor Hongfei Duan from the Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, delivered a fascinating presentation titled "Advances in Diagnosis and Treatment of Mycobacterium avium Complex Pulmonary Disease," elucidating and analyzing the current status, challenges, and progress in the diagnosis and treatment of MAC pulmonary disease.